BRIEF published on 11/10/2025 at 21:55, 2 months ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 2 months ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 3 months 17 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
PRESS RELEASE published on 09/23/2025 at 21:40, 3 months 17 days ago Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 Integrated BioPharma, Inc. reports 11.8% increase in revenue for Q2 2025. Operating income rises in Q2 & FY 2025. Net loss in Q2 but net income grows for FY 2025 Revenue Increase Net Income Net Loss Operating Income Integrated BioPharma
BRIEF published on 05/14/2025 at 21:35, 7 months 27 days ago Integrated BioPharma, Inc. Posts Financial Results for Q1 2025 Financial Results Revenue Growth Operating Income Q1 2025 Key Customers
PRESS RELEASE published on 05/14/2025 at 21:30, 7 months 27 days ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Integrated BioPharma, Inc. reports a 6.1% revenue increase for Q1 2025 compared to Q1 2024. Company had operating income and net income growth. Key focus on core business and expanding customer base Financial Results Revenue Increase Net Income Operating Income Integrated BioPharma
BRIEF published on 02/13/2025 at 22:00, 10 months 25 days ago Integrated BioPharma Reports Quarterly Results with Increased Revenue Revenue Growth Q4 Results Operating Income Customer Base Expansion Integrated BioPharma
PRESS RELEASE published on 02/13/2025 at 21:55, 10 months 25 days ago Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024 Integrated BioPharma, Inc. reports 9.6% increase in revenue to $12.6 million for quarter ended Dec 31, 2024. Operating income of $0.2 million. Detailed financial results provided Financial Results Revenue Increase Quarterly Report Operating Income Integrated BioPharma
BRIEF published on 11/13/2024 at 23:38, 1 year 1 month ago Integrated BioPharma, Inc. Announces Q3 2024 Financial Results Revenue Growth Net Income Integrated BioPharma Customer Diversification Q3 2024 Results
PRESS RELEASE published on 11/13/2024 at 23:33, 1 year 1 month ago Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024 Integrated BioPharma, Inc. reports revenue growth in Q3 2024 with net income of $0.3 million. Diversification of customer base leads to increased financial performance Revenue Growth Financial Performance Diversification Q3 2024 Integrated BioPharma
Published on 01/10/2026 at 05:10, 1 day 14 hours ago Sekur Private Data Ltd. Announces Non-Brokered Private Placement
Published on 01/10/2026 at 00:45, 1 day 19 hours ago Digi Power X Announces Entry into Settlement Agreement
Published on 01/09/2026 at 23:30, 1 day 20 hours ago Matador Technologies Announces Grant of Restricted Share Units to Management Team
Published on 01/09/2026 at 23:10, 1 day 20 hours ago Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction
Published on 01/10/2026 at 21:25, 22 hours 35 minutes ago CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
Published on 01/10/2026 at 13:05, 1 day 6 hours ago SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation
Published on 01/09/2026 at 21:55, 1 day 22 hours ago Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Published on 01/09/2026 at 18:36, 2 days 1 hour ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/09/2026 at 18:19, 2 days 1 hour ago EQS-Adhoc: BayWa AG: Change in the Board of Management of BayWa AG
Published on 01/09/2026 at 18:30, 2 days 1 hour ago H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 2 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 2 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
Published on 01/08/2026 at 21:00, 2 days 23 hours ago Biannual report on SEB S.A.’S liquidity agreement